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Abstract 
Oral anticoagulants are required for both treatment and prophylaxis in many different 
diseases.  Clinicians and patients now have a choice of oral anticoagulants, including the 
vitamin K antagonists (of which warfarin is the most widely used, and is used as the exemplar 
in this paper) and direct oral anticoagulants (DOACs: dabigatran, apixaban, rivaroxaban and 
edoxaban).  The paper explores the recent advances and controversies in oral 
anticoagulation.  While some commentators may favour a complete switchover to DOACs, 
this paper argues that warfarin still has a place in therapy, and a stratified approach that 
enables the correct choice of both drug and dose, would improve both patient outcomes and 
affordability. 
Introduction 
Warfarin is more than 60 years old. With the advent of the direct oral anticoagulants (DOACs), 
some commentators have suggested that the end for warfarin is nigh [1]. However, it may be 
premature to write an obituary for warfarin, given its widespread use worldwide, and the 
inability to use warfarin in some patient groups, for example in children, in patients with renal 
impairment and in patients with heart valves.  Furthermore, given the cost of the DOACs, 
there may still be a place in clinical practice for a stratified approach to anticoagulation. This 
article examines the history of warfarin use, and in particular, the role of pharmacogenetics, 
and looking into the future, what still needs to be done to improve the benefit-risk ratio for 
all oral anticoagulants. 
Warfarin pharmacology and pharmacogenetics 
Warfarin is a vitamin K antagonist; it inhibits vitamin K epoxide reductase complex I (VKORC1), 
preventing the formation of activated vitamin K-dependent coagulation factors II, VII, IX and 
X [2].  The gene VKORC1 is polymorphically expressed, which leads to variable expression and 
activity of the enzyme; for example, the -1639A variant at rs9923231 leads to reduced mRNA 
levels [3]. Warfarin is administered as a racemate, with the more potent enantiomer S-
wafarin being metabolised by the P450 isoform CYP2C9 [2].  CYP2C9 genetic variants show 
reduced activity; for example CYP2C9*3 is associated with a 90% reduction in catalytic activity 
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of the enzyme [4].  It is interesting to note that the frequencies of both VKORC1 and CYP2C9 
genetic polymorphisms vary with ethnicity, which has an impact on dose requirement 
worldwide [5,6] – it is widely acknowledged that African patients generally require higher 
doses than Caucasians while Chinese patients require lower doses. 
There is no argument that warfarin is an effective drug for the treatment of venous 
thromboembolism, and for prophylaxis against strokes in patients with atrial fibrillation [7].  
However, warfarin is also associated with bleeding, estimated to be about 7.2 events per 100 
years [8]. Indeed, warfarin is amongst the top 3 drugs responsible for adverse drug reaction 
related hospital admissions [9].  The major issue with warfarin is the inability to predict inter-
individual variability in daily dose requirements. Some patients require 0.5mg per day to 
maintain therapeutic anticoagulation, for example, an INR between 2 and 3 in the treatment 
of atrial fibrillation, while others may require 20mg per day, variability of more than 40-fold. 
We have known for many decades that this variability is partly dependent on clinical factors, 
such as age, BMI, drug-drug interactions, and concomitant diseases [2]. However, apart from 
age, none of these clinical predictors have routinely been utilised in dosing regimens. 
In order to improve the predictability of daily warfarin dose requirements, many groups 
worldwide have evaluated the role of genetic and clinical factors.  These studies have 
consistently shown that genetic polymorphisms in CYP2C9 and VKORC1 account for a greater 
degree of variance in daily dose requirement compared with clinical factors such as age, BMI 
and interactions with drugs such as amiodarone [10,11]. Indeed, the association of warfarin 
dose requirement with genetic factors is one of the most highly replicated genotype-
phenotype associations.  Another genetic factor associated with warfarin dose requirement 
is the CYP4F2 genetic variant at rs2108622 (V433M) [12], the effect being due to differential 
vitamin K hydroxylation [13]. However, the overall effect size of CYP4F2 is much lower than 
that of CYP2C9 and VKORC1, accounting for about 1% of the variability in warfarin dose 
requirement [14]. 
One of the most important developments in warfarin pharmacogenetics was the formation 
of the International Warfarin Pharmacogenetics Consortium (IWPC) that brought together 21 
research groups from nine countries and four continents, with analysable data from about 
5000 patients [15]. The IWPC developed clinical and genetic warfarin dosing algorithms. The 
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genetic dosing algorithm was superior to the clinical dosing algorithm, with the greatest 
benefit being observed in about half of the patients who required either less than 21mg of 
warfarin per week, or more than 49mg/week. 
An important next step in the demonstration of the utility of genotype-guided dosing for 
warfarin was to demonstrate whether the genetic algorithm was superior to either standard 
care or a clinical algorithm. A number of clinical trials had already been conducted in this area 
with variable designs and disparate sample sizes, with inconclusive findings [16]. Because of 
this, two larger RCTs were undertaken, one in the US (COAG) [17], and another in the EU (EU-
PACT) [18]. There were numerous differences in the design of the two trials [16], with COAG 
comparing a clinical algorithm to a genetic algorithm, while EU-PACT compared standard care 
in two European countries (UK and Sweden) to the genetic algorithm. Unfortunately, but 
perhaps not surprisingly given the differences in trial design, the results of the two trials were 
starkly different, with EU-PACT showing superiority of the genetic algorithm over the 
comparator arm [19], while in COAG there was no difference between the test and control 
arms [20].  This led to confusion and criticisms of both trials, and the conclusion that 
pharmacogenetic dosing of warfarin was not clinically useful [21,22].  Perhaps, this is 
consistent with the recent paper in Science which highlighted that negative stories are more 
likely to get traction when compared with positive news [23].  Interestingly, following the 
publication of the trials, it was also suggested that dosing should be based on a clinical 
algorithm, rather than the standard dosing currently used in clinical care, despite the fact that 
there has been no RCT that has compared a clinical algorithm to standard of care.  This is 
perhaps another example of genetic exceptionalism, where a lower burden of proof is 
considered acceptable for non-genetic interventions, when compared with genetic testing.  
In retrospect, it would have been better to conduct 3-armed trials where genotype-guided 
dosing was compared simultaneously with both a clinical algorithm and standard dosing. 
The reasons for the different outcomes in the two trials have been widely debated, and 
included differences in algorithms, differences in the comparator arms and greater ethnic 
heterogeneity in COAG compared with EU-PACT [16]. The design of any algorithm is of course 
crucial, and it must take into account the ethnic heterogeneity (including the relevant ethnic-
specific SNPs) and the known pharmacology of warfarin including its long half-life.  It is also 
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fair to state that no algorithm is perfect, because not all factors that determine warfarin 
dosing have been identified [10].  The algorithms also predict extreme doses less efficiently 
(i.e. low or high daily warfarin doses) [15,24].  Algorithms designed for African-American, 
Indian and Chinese patients have been developed but have not been tested in clinical trials 
[25-27]. 
More recently, the GIFT trial has been published [28], conducted in 1650 randomised patients. 
This used a composite primary outcome measure comprising major bleeding, INR of 4 or 
greater, venous thromboembolism, or death. The trial found that 10.8% of the genotype-
guided group met at least one of the end-points compared with 14.7% in the clinically guided 
warfarin group, a 27% improvement in favour of genotype guided dosing.  The results are 
consistent with EUPACT [19], but GIFT has the advantage of having included clinical outcomes 
as part of the primary end. point. Indeed, EUPACT and COAG were both criticised for having 
used percentage time in therapeutic range (%TTR), a surrogate measure, as the primary 
outcome measure [22].  Of course, a trial that used only clinical events (thromboembolic or 
bleeding) as the primary outcome would be preferable but would have required a sample size 
close to 20,000 patients. It is also important to note that an improvement in %TTR greater 
than 10% can lead to a 20% improvement in clinical outcomes [29]. 
From the EU-PACT trial data, it has been shown that genotyping prior to warfarin prescription 
would be cost effective in both the UK and Sweden [30].  Data on cost-effectiveness from 
other healthcare systems is awaited [31].  The 2017 Clinical Pharmacology Implementation 
Consortium (CPIC) guideline on warfarin provides detailed guidance on dosing in patients with 
variant alleles, including race-specific recommendations [32].  The Dutch Pharmacogenetic 
Working Group has also developed guidelines for dosing of vitamin K antagonists, and there 
is a high overall rate of concordance between guidelines produced by the Dutch group and 
CPIC [33].  
Direct oral anticoagulants 
Oral anticoagulants acting via the Vitamin K-dependent pathway were the only choices 
available for clinicians until recently. The introduction of direct acting oral anticoagulants 
(DOACs) has provided greater choice for both clinicians and patients. These drugs act by 
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inhibiting either thrombin (dabigatran) or factor Xa (apixaban, rivaroxaban, edoxaban). Large 
randomised controlled trials in AF and venous thromboembolism have shown that DOACs are 
either non-inferior or superior to warfarin, with a reduced risk of intracranial haemorrhage, 
but with a possibly increased risk of gastro-intestinal bleeding [34]. 
DOACs have been marketed on the basis that "one-dose-fits-all" and that no monitoring is 
required. There has been rapid uptake of these drugs particularly in western countries, while 
the use of warfarin has declined [1].  This may well herald the beginning of the end for 
warfarin, but I feel this is premature for several reasons. 
First, although the new DOACs have been shown to be cost-effective [35], there are concerns 
about the cost outlay given the large population that needs to be treated. It has been 
estimated that there are 8.8 million people with AF in the European Union and this will double 
to 17 million in 2060 [36].  In the UK, it has been estimated that expenditure on DOACs may 
top £1 billion per year by 2020, about 5% of the overall spend on drugs in the NHS [37]. One 
possible method to improve affordability and ensure all patients have access to oral 
anticoagulation would be to stratify treatment according to genotypes for CYP2C9 and 
VKORC1. The evidence for this comes from analyses of the warfarin arm in the edoxaban 
ENGAGE AF-TIMI 48 trial [38]. This showed that edoxaban reduced the risk of bleeding in 
those patients who carried variant alleles for CYP2C9 and/or VKORC1 such that they were 
classified as sensitive or highly sensitive responders, when compared with normal responders 
who represent 62% of the population.  A more recent analysis of the Hokusai-venous 
thromboembolism trial [39] has replicated this finding, showing that sensitive and highly 
sensitive responders spent more time over-anticoagulated and had a higher bleeding risk 
compared with normal responders (who represented 63% of the population).  Thus, it may 
be possible to personalise the use of oral anticoagulants in the future so that patients with 
the low risk genotypes (i.e. normal responders, at least 60%) would get warfarin, while those 
classified as sensitive or highly sensitive would get DOACs. This would lead to significant 
savings in expenditure [37], without any compromise in clinical outcomes. 
An important issue to consider for taking forward the stratification approach is whether it is 
possible to implement warfarin genotyping in a clinical setting. Following the EU-PACT trial 
[19], and despite the conflicting results with COAG [20], we have undertaken an 
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implementation study. The premise behind the study was to determine whether staff running 
anticoagulant clinics (predominantly qualified nurses) could modify the current clinical 
pathway so that genotyping, and subsequent genotype-guided dosing, could be incorporated. 
This required an improvement in the point-of-care genotyping assay. In EU-PACT, the point-
of-care genotyping platform was able to provide results on 3 alleles (CYP2C9*2, CYP2C9*3, 
and VKORC1) in 2 hours [19]. For the implementation study, the platform was modified to 
provide results within 45 minutes. The results of the implementation study (unpublished) 
were equivalent to those of our EU-PACT RCT demonstrating that long and well-established 
clinical pathways could be modified using new technologies. 
Second, an unintended consequence of the "no or minimal monitoring" strategy adopted for 
DOACs may be poor adherence. Our recent data suggest that adherence to DOACs was 
significantly worse when compared with warfarin [37].  Although INR monitoring is disliked 
by both patients and clinicians, it does act as a positive reinforcement for patents to continue 
taking warfarin.  It is important to note that there has also been criticism of the "one-dose- 
fits all" strategy for DOACs, with some patients having been shown to be under-dosed, while 
others may be over-dosed [40]. Pharmacogenomic studies have identified some associations 
with plasma concentrations of these drugs, but none of these are likely to be useful in 
improving the clinical use of these drugs [41,42].  It has been argued that plasma therapeutic 
drug monitoring should be utilised [43], especially in high-risk patients to individualise dose. 
High-risk groups could include patients at high risk of bleeding, those on drugs likely to 
interact with DOACs, and patients with borderline renal impairment, to name a few. Clearly, 
this would lead to a loss of the marketing advantage for DOACs, and increase cost and 
inconvenience for patients, and may thus face an uphill battle for implementation. 
Third, there are some patients where DOACs are not used because of contra-indications, no 
marketing authorisation or unaffordability.  In these situations (outlined below), warfarin 
remains the only alternative.  
(a) Patients with renal impairment: all the drug labels for DOACs have criteria which either 
recommend a dose reduction, or absolutely contraindicate the use of the DOAC [44].  While 
it may be relatively easy to avoid the use of DOACs in patients with severe forms of renal 
impairment, a group that may be at particular risk are patients with incipient renal 
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impairment, where there may be incipient decline in renal function with age, or an acute 
decline in an elderly patient because of a concomitant urinary tract infection.  This is 
compounded by the fact that monitoring of renal function in patients on DOACs is poorly 
performed.   
(b) Patients on interacting drugs: Although DOACs are less likely to be involved in drug-drug 
interactions than warfarin, they are not immune from them.  For patients on certain 
medications, for example itraconazole, the use of apixaban is not recommended. A recent 
database study from Taiwan showed that concomitant use of drugs such as  amiodarone, 
fluconazole, rifampicin, and phenytoin increased the risk of major bleeding when compared 
with the use of DOACs alone [45].  There is no simple biomarker that can be used to 
individualise dosing with DOACs, unlike warfarin, where INR monitoring provides the 
opportunity to change dose to maintain the INR within a therapeutic range.   
(c) Use in children: DOACs are currently not licensed for use in children, but there are 
paediatric investigation plans in place [46]. Thus, for the time being, warfarin (or other vitamin 
K antagonists) remain the only alternatives.  There have been numerous studies in children 
investigating the effects of genetic polymorphisms on warfarin dosing [47-50], but no 
algorithm has been tested in clinical trials.  
(d) Mechanical heart valves:  DOACs are currently contra-indicated in patients with 
mechanical heart valves.  In the RE-ALIGN trial, after enrolment of 252 patients, an increased 
risk of bleeding and thrombosis was seen in patients on dabigatran, compared with warfarin, 
which resulted in premature discontinuation of the trial [51].   
Fourth, because of the cost of DOACs, their uptake in developing countries has been low, and 
thus warfarin (or other vitamin K antagonists) remain the main choice. Unfortunately, genetic 
and clinical factors affecting warfarin dose variation have been poorly studied in developing 
countries, and even in developed in minority groups compared with Caucasian populations 
[6]. The frequencies of genetic variants in CYP2C9 and VKORC1 vary with ethnicity. Thus, in 
Chinese patents CYP2C9*2 is less important than in Caucasians [52].  In African-Americans, 
both CYP2C9*2 and CYP2C9*3 have a low prevalence, with other variant alleles (*8, *11) 
being more important [6]. The importance of this was highlighted by the COAG trial [20] 
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where genotype-guided dosing actually fared worse than clinical dosing in African-American 
patients. In Africa, where access to medicines and services is limited, warfarin remains the 
obvious choice of oral anticoagulant. However, dosing regimens are largely empirical and not 
evidence based, which coupled with the lack of infrastructure leads to poor quality of 
anticoagulation.  For example, in South Africa, a recent study showed that only 28% of 
patients achieved a therapeutic INR [53]. The importance of achieving better anticoagulation 
control in developing countries is shown by a study in South Africa which demonstrated that 
haemorrhage was the fourth most common cause of hospital admission, with warfarin 
accounting for 68% of the bleeds [54]. We have recently embarked on a large programme of 
work in Uganda and South Africa (War-PATH: WARfarin anticoagulation in PATients in Sub-
SaHaran Africa; http://warpath.info/), the aim of which is to identify the clinical and genetic 
factors determining variation in daily warfarin dose requirement and thereby develop better 
clinical and genetic dosing algorithms to improve anticoagulation quality. 
 
Conclusions 
It has been estimated that the global anticoagulants market will be worth close to $30billion 
by 2021 (https://www.businesswire.com/news/home/20170301005087/en/Increase-
Lifestyle-Diseases-Boost-Global-Anticoagulant-Market).  For both clinicians and patients, it is 
important to have a choice of drugs to use for either treatment or prophylaxis, and the 
availability of DOACs has certainly provided that choice.  However, that does not mean that 
older drugs have no place in the therapeutic armamentarium, as I have pointed out for 
warfarin.  Undoubtedly, we can continue to improve the benefit-risk ratio of all oral 
anticoagulants that are available, and a stratified approach to the choice of drug, and the 
precise dose of that drug (figure 1), may be an option that not only maximises the positive 
clinical outcomes, but also improves affordability and access.  Whether this would be a cost-
effective approach would need further study; however, it is clear that the cost-effectiveness 
of DOACs is reduced or nullified when the quality of anticoagulation with warfarin improves 
[55], which is likely to be the consequence of a stratified approach.   
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Figure 1 
Clinical pathways for stratification in the use of oral anticoagulants.  Use of either warfarin or 
a direct oral anticoagulant (DOAC) would require individualisation of dose to improve time in 
therapeutic range, and optimisation of anticoagulation, resulting in improved clinical 
outcomes.  This would also result in increased affordability. 
